Our History
1837
Carlo Erba pharmacy and laboratory established
1936
Farmitalia established, acquires farming estate in Nerviano as veterinary outstation
1974
First ever anthracycline (Adriamycin) approved by FDA
1978
Farmitalia-Carlo Erba merge to form Farmitalia/Carlo Erba (FICE)
1993
FICE acquired by Kabi- Pharmacia To form Pharmacia
1995
Pharmacia merge with The Upjohn Company to become Pharmacia&Upjohn (PNU)
1997
PNU acquire SUGEN, becoming leaders of the kinase field
1999
Aromasin approved by FDA
2000
PNU merge with Searle/Monsanto to become Pharmacia
2003
Pharmacia Acquired by Pfzier
2004
Nerviano site spun off by Pfzier, acquired by CFIC and renamed as “Nerviano Medical Sciences, srl”, (NMS)
2010-2011
Encorafenib enabling IP licensed to Novartis.
Kinase platform agreement with Pfizer renegotiated, and a Region of Lombardy research foundation, “Fondazione Regionale per la Ricerca Biomedica (FRRB) takes over financial control of NMS
2012
Entrectinib, Phase I sponsored by NMS, enters FIH clinical testing, in 3 separate, rationally selected indications.
2018
Encorafenib approved by FDA in 2 independent indications.
Major stake in NMS is acquired by a Shanghai-based Chinese Venture Group, Hefei SARI V-Capital Management Co.
2019
Entrectinib approved by FDA in 2 independent indications
2019-2020-2021
NMS M801; P707; P912 and P807, all targeting different BIC/FIC mechanisms, programs start independent, mutinational, FIH clinical trials
2022
Nerviano Medical Sciences S.r.l. expands US presence: subsidiary’s
Nerviano Medical Sciences Inc. story begins.

People/Team

Collaboration and Partnership


Publication
People/Team




Publication